Abstract:Abstract Hematopoietic stem cell transplantation (HCT) is an effective therapeutic option for many cancers and disorders of immune dysfunction. However, acute graft versus host disease (GVHD) remains a morbid complication of HCT, caused by donor T cells attacking the recipient's organs. GVHD can be severe, resulting in multiorgan failure and death. Current immunosuppressive therapies remain marginally effective. The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is emerging as a master regulator of the immune system. It is required for lymphocyte maturation and immune system diversity due to its role in V(D)J recombination. Our published data and others have determined that DNA-PKcs is required for cytokine expression, namely IL2, IL4, IL6, IL10, IFN, and TNF. Therefore, we hypothesized that DNA-PKcs inhibitors could serve as effective immunosuppressants for transplant patients to prevent rejection, which we tested in a murine allogeneic skin graft model. Ear skin from Balb/c mice was transplanted onto the backs of C57bl/6 or DNA-PKcs null mice (KO). C57bl/6 mice were treated with saline, FK506, or NU7441, a potent and selective DNA-PKcs inhibitor. Treatment with NU7441 significantly reduced graft rejection compared to both saline and FK506. Similar levels were observed in the KO mice, with less than 10% rejection after 10 days when a majority of the controls were completely rejected. These results led us to hypothesize that DNA-PKcs is required for cytotoxic activity of T cells, highlighting the potential use of DNA-PKcs inhibitors to prevent and/or treat GVHD in HCT patients . In order to evaluate the role of DNA-PKcs on T cell activation, we isolated CD8+ T cells from mouse spleens using negative selection via magnetic column. The T cells were then activated with anti-CD3/CD28 for 24-48 hours in the presence of NU7441 or vehicle (DMSO), and the cells were analyzed by flow cytometry. A fully activated T cell expresses both CD69 (early) and CD25 (later) on the surface. T cells that had been activated with NU7441 had a higher expression of CD69 and lower expression of CD25 (figures 1&2). These results are even more pronounced after 48 hours, with a much lower percent of cells expressing both CD69 & CD25 compared to T cells that had been activated in the presence of DMSO alone (figure 3). This suggests that DNA-PKcs plays a role in the activation pathway of cytotoxic T cells - the T cells are blocked from becoming completely activated as evidenced by a significant decrease in cells expressing both CD69 and CD25. If DNA-PKcs is required for the complete activation of CD8+ T cells, this may have therapeutic implications in the prevention of GVHD as cytotoxic T cells are required to cause the pathophysiologic manifestations of GVHD. We then addressed whether DNA-PKcs affects the expression of cytotoxic genes in CD8+ T cells. The T cells were isolated and activated in the presence of NU7441 or vehicle as described above. Total RNA was then isolated from the activated T cells, and qPCR was performed to assess the difference in cytotoxic gene expression. Several genes required for cytotoxic function of CD8+ T cells, including perforin-1, granzyme, and eomes. IL2Ra is the gene coding the CD25 surface marker/IL2 receptor. CTLA4 and TGFb are associated with immune tolerance. A statistically significant decrease in gene expression was seen when treating with NU7441 in the expression of granzyme (p-value 0.01), eomes (p-value <0.01), and IL2Ra (p-value 0.04). While other data was not statistically significant, an interesting trend was seen in increased expression of TGFb. Overall, the significant data suggests that DNA-PKcs plays a role in the expression of certain cytotoxic genes, and may lead to overall decreased cytotoxic activity, perhaps by both decreasing expression of certain genes required for cytotoxic activity/cytokine production as well as increasing the expression of other genes involved in immune tolerance. Both of these effects could potentially lead to a favorable outcome in prevention of acute GVHD. This data serves as an excellent proof of concept for testing the hypothesis that DNA-PKcs inhibitors can prevent acute GVHD in an animal model. This preclinical model would potentially lay the foundation to move into preclinical studies and eventually phase I clinical trials to prevent and/or treat GVHD, creating a new therapeutic option for a morbid complication for HCT patients. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Pharmacologic Inhibition Of Pkc Alpha And Pkc Theta Prevents Gvhd While Preserving Gvl Activity In Mice

Genetic and Pharmacologic Inhibition of PKCθ and PKCα Prevents Acute Gvhd While Sparing GVL Activity in Mice.

Effective Prevention Of Acute Graft-Verses-Host Disease By Targeting Pkc Alpha And Pkc Theta In Mice

Targeting PKCtheta Inhibits Alloreactivity and Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia and Anti-Infection Activities.

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

PKCθ is Required for Alloreactivity and GVHD but Not for Immune Responses Toward Leukemia and Infection in Mice

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT

Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice

Targeting Pkc Theta In Alloreactivity And Graft-Versus-Host-Disease: Unanswered Questions And Therapeutic Potential

Inhibition of DNA-Pkcs As Novel Therapy for the Prevention of Acute Gvhd Following Hematopoietic Stem Cell Transplantation

[Experimental Study of Tripterygium Hypoglaucum (level) Hutch on Preventing Acute Graft-Versus-host Disease in Bone Marrow Transplantation Mice].

Tetramerization of pyruvate kinase M2 attenuates graft-versus-host disease by inhibition of Th1 and Th17 differentiation

Caspase 1 Inhibitor Ac-YVAD-CMK Prevents and Treats the Acute Graft Versus Host Disease in Mice

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease

Low-dose Post-Transplant Cyclophosphamide Can Mitigate GVHD and Enhance the G-CSF/ATG Induced GVHD Protective Activity and Improve Haploidentical Transplant Outcomes.

Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease

Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation

Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect

Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor Ameliorates Acute Graft-versus-Host Disease by Inhibiting Effector T Cell Differentiation while Sparing Regulatory T Cells

Targeting JAK2 by Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection by Promoting Induced Treg Differentiation

Post-transplant cyclophosphamide with post-engraftment anti-thymocyte globulin reduce moderate to severe chronic graft-versus-host disease in peripheral stem cell transplantation from HLA-matched unrelated and haploidentical donors